Drugs / Allogeneic human menstrual blood stem cells secretome
Allogeneic human menstrual blood stem cells secretome
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05019287 | Apr → May 2021 | COVID-19, cytokine release syndrome | Avicenna Research Institute | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic human menstrual blood stem cells secretome | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05019287 ↗ |
| Known as | MenSC-derived secretome | “Patients with severe COVID-19 were randomized (1:1) to either MenSC-derived secretome treatment or the control group.” PMID 35255966 ↗ Mar 2022 |
| Known as | MenSCs-derived secretome | “CONCLUSIONS: For the first time, this study demonstrated that in hospitalized patients with severe COVID-19, therapy with MenSCs-derived secretome leads to reversal of hypoxia,...” PMID 35255966 ↗ Mar 2022 |
| Modality | Other / unclassified | “These active molecules could potentially serve as a biological therapeutic agent for treating the severe SARS-CoV-2 infection.” NCT05019287 ↗ |
| Route | Intravenous | “Subjects received five intravenous infusions of 5 mL secretome or the same volume of placebo for five days” PMID 35255966 ↗ Mar 2022 |